References

  1. Acharya KG, Shah KN, Solanki ND, Rana DA. Evaluation of antidiabetic prescription, cost and adherence to treatment guidelines; a prospective, cross-sectional study at a tertiary care teaching hospital. J Basic Clin Pharm. 2013 Sep; 4(4): 82-7. PubMed | Google Scholar

  2. International Diabetes Federation. Middle East and North Africa. 2015. Google Scholar

  3. World Health Organization. diabetes mellitus: report of a WHO study group. Geneva, world HealthOrganization Tech Report Ser No 727. 1985. Google Scholar

  4. Ahmed AM. Diabetes mellitus in Sudan: size of the problem and possibilities of efficient care. Pract Diabetes Int. 2001 November; 18(9): 324-327. Google Scholar

  5. Diabetes Care. Summary of revisions for the 2010 clinical practice recommendations. Diabetes Care. 2010 Jan; 33(Supplement 1): S3. PubMed | Google Scholar

  6. Hermansen K, Mortensen LS, Hermansen ML. Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease. Vasc Health Risk Manag. 2008 Jun; 4(3): 561-74. PubMed | Google Scholar

  7. Sivasankari V, Manivannan E, Priyadarsini SP. Drug utilization pattern of anti-diabetic drugs in a rural area of Tamilnadu, South India: a prospective, observational study. Int J Pharm BiolSci. 2013; 4: 514-9. Google Scholar

  8. FisherL, Gonzalez, JS,Polonsky WH. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. Diabet Med. 2014 Jul; 31(7): 764-772. PubMed | Google Scholar

  9. Fisher L, Mullan JT, Arean P, Glasgow RE, Hessler D, Masharani U. Diabetes distress and not clinical depression or depressive affect is associated with glycemic control in both cross-sectional and longitudinal analyses. Diabetes Care. 2010 Jan; 33(1): 23-28. PubMed | Google Scholar

  10. National Institute on Aging/National Institute of Health. Gloabal health and aging. World Health Organization NIH Publication. 2011; 11-7737. Google Scholar

  11. Jung YH. A study on the effective chronic disease management. Korea Institute for Health and Social Affairs: Korea Institute for Health and Social Affairs. 2013; 2013-31-19. Google Scholar

  12. Frazier SC. Health outcomes and polypharmacy in elderly individuals: an integrated literature review. Journal of gerontological nursing. 2005 Sep; 31(9): 4-11. PubMed | Google Scholar

  13. Fried TR, O'Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. Journal of the American Geriatrics Society. 2014 Dec; 62(12): 2261-72. PubMed | Google Scholar

  14. Park HY, Park JW, Song HJ, Sohn HS, Kwon JW. The Association between Polypharmacy and Dementia: a Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea. PLoS One. 2017 Jan 5; 12(1): e0169463. PubMed | Google Scholar

  15. Rogvi S, Tapager I, Almdal TP, Schiotz ML, Willaing I. Patient factors and glycaemic control?associations and explanatory power. Diabet Med. 2012 Oct; 29(10): e382-e389. PubMed | Google Scholar

  16. Chew BH, Vos R, Mohd-Sidik S, Rutten GE. Diabetes-Related Distress, Depression and Distress-Depression among Adults with Type 2 Diabetes Mellitus in Malaysia. PLoS One. 2016 Mar 22; 11(3): e0152095. PubMed | Google Scholar

  17. Siaw MY, Tai BB, Lee JY. Psychometric properties of the Chinese version of the Problem Areas in Diabetes scale (SG-PAID-C) among high-risk polypharmacy patients with uncontrolled type 2 diabetes in Singapore. J Diabetes Investig. 2017 Mar; 8(2): 235-242.. PubMed | Google Scholar

  18. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003 May; 26(5): 1408-12. PubMed | Google Scholar

  19. Tandon VR. Metformin Therapy: Benefits beyond glycaemic Control. International Journal of Diabetes in Developing Countries. 2007 Jan-March; 27(1): 1-4. Google Scholar

  20. Johnson JA, Pohar SL, Secnik K, Yurgin N, Hirji Z. Utilization of diabetes medication and cost of testing supplies in Saskatchewan, 2001. BMC Health Serv Res. 2006 Dec; 6: 159. PubMed | Google Scholar

  21. Ruiter R, Visser LE, van Herk-Sukel MP, Geelhoed-Duijvestijn PH, de Bie S, Straus SM, Mol PG, Romio SA, Herings RM, Stricker BH. Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008. Drug Saf. 2012 Jun; 35(6): 471-80. PubMed | Google Scholar

  22. Hostenkamp G, Fischer KE, Borch-Johnsen K. Drug safety and the impact of drug warnings: an interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark. Health Policy. 2016 Dec; 120(12): 1404-1411. PubMed | Google Scholar